Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DRL_RI||DRL-rituximab||CD20 Antibody 21||DRL_RI is a potential biosimilar of rituximab, which may lead to complement and antibody-dependent cytotoxicity towards CD20-positive tumor cells (PMID: 31809224).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03976102||Phase III||Rituximab DRL_RI||Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (FLINTER)||Active, not recruiting||USA||0|